Overview

Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To study the impact of CYP2C19 polymorphism on escitalopram pharmacokinetics and pharmacodynamics measured as changes in pupil diameter
Phase:
Phase 4
Details
Lead Sponsor:
University of Southern Denmark
Collaborator:
H. Lundbeck A/S
Treatments:
Citalopram
Dexetimide